New Mass Spectrometry Method Precisely Measures Synuclein Proteins Linked to Parkinson's Disease

Researchers developed a precise mass spectrometry assay that can separately quantify different forms of synuclein proteins in brain tissue, improving Parkinson's disease research tools.

Singh, Serena et al.·Journal of Parkinson's disease·2020·Preliminary Evidencemethods paper
RPEP-05141Methods paperPreliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
methods paper
Evidence
Preliminary Evidence
Sample
N=small
Participants
M83 transgenic PD mice and wild-type littermate controls

What This Study Found

The MRM LC-MS/MS assay quantifies total alpha-synuclein, species-specific contributions, combined alpha/beta-synuclein, and post-translational modification signatures in a single streamlined analysis with wide linear range.

Key Numbers

6 proteotypic peptides; 3 species-specific; 3 conserved; linear over ≥1 order of magnitude

How They Did This

Development and validation of a multiple reaction monitoring LC-MS/MS assay using proteolytic digestion of six proteotypic peptides, labeled internal standards, and external calibration curves. Validated in M83 transgenic PD mouse brain tissue versus wild-type controls.

Why This Research Matters

Better tools to measure synuclein proteins are essential for Parkinson's disease research. This method provides more detailed and reliable measurements than existing techniques, potentially accelerating preclinical drug development.

The Bigger Picture

Synuclein aggregation is central to Parkinson's disease pathology. Having precise tools to measure different synuclein forms could improve our understanding of disease progression and help evaluate whether experimental therapies actually reduce pathological synuclein levels.

What This Study Doesn't Tell Us

Validated only in transgenic mouse brain tissue with a small sample size. Application to human tissues and biofluids like cerebrospinal fluid remains to be demonstrated. The method measures soluble synucleins but may not capture aggregated forms.

Questions This Raises

  • ?Can this assay be adapted to measure synuclein in human cerebrospinal fluid or blood for diagnostic purposes?
  • ?How well does the method detect aggregated or phosphorylated synuclein forms most relevant to disease?
  • ?Could this platform be used to monitor treatment response in Parkinson's disease clinical trials?

Trust & Context

Key Stat:
4-in-1 analysis Measures total alpha-synuclein, species-specific forms, combined alpha/beta, and post-translational modifications in a single run
Evidence Grade:
Rated preliminary because while the analytical method is well-developed, it has only been validated in a small number of transgenic mouse samples and has not yet been applied to human tissue.
Study Age:
Published in 2020, this methods paper addresses ongoing analytical challenges in synuclein research that remain relevant today.
Original Title:
Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.
Published In:
Journal of Parkinson's disease, 10(2), 613-621 (2020)
Database ID:
RPEP-05141

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are synucleins and why do they matter in Parkinson's disease?

Alpha-synuclein is a protein that misfolds and clumps together in the brains of Parkinson's patients, forming toxic aggregates called Lewy bodies. Measuring synuclein levels precisely helps researchers understand the disease and test potential treatments.

Why is this method better than existing protein measurement techniques?

Unlike western blots or ELISAs, this mass spectrometry method can distinguish between mouse and human synuclein, measure multiple synuclein types simultaneously, and detect structural modifications — all in a single test with greater quantitative precision.

Read More on RethinkPeptides

Cite This Study

RPEP-05141·https://rethinkpeptides.com/research/RPEP-05141

APA

Singh, Serena; Khayachi, Anouar; Milnerwood, Austen J; DeMarco, Mari L. (2020). Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.. Journal of Parkinson's disease, 10(2), 613-621. https://doi.org/10.3233/JPD-191835

MLA

Singh, Serena, et al. "Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.." Journal of Parkinson's disease, 2020. https://doi.org/10.3233/JPD-191835

RethinkPeptides

RethinkPeptides Research Database. "Quantitative Profiling of Synuclein Species: Application to ..." RPEP-05141. Retrieved from https://rethinkpeptides.com/research/singh-2020-quantitative-profiling-of-synuclein

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.